REGENXBIO (RGNX) Stock: Buy, Sell, or Hold?
RGNX - REGENXBIO Inc.
$6.74
-0.43 (-6.00%)
▼
5d:
-2.67%
30d:
-6.91%
90d:
-30.59%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
12d
Get Alerted When RGNX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: RGNX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: RGNX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: RGNX is currently trading at $6.74, which is considered oversold relative to its 30-day fair value range of $7.13 to $8.00.
Technical Outlook: Technically, RGNX is in a downtrend. The price is currently testing key support at $6.68. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.0% recently.
Market Sentiment: RGNX scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $23.58 (+228.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RGNX is in a downtrend. The price is currently testing key support at $6.68. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.0% recently.
Market Sentiment: RGNX scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $23.58 (+228.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.13 -
$8.00
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (28/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.0%)
- BULLISH: Trading 228.9% below Wall St target ($23.58)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.13 -
$8.00
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$6.68
Resistance Level
$8.29
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.41
Wall Street Target
$23.58
(+228.9%)
Revenue Growth (YoY)
405.7%
Profit Margin
-112.6%
Share & Embed Analysis
Last updated: October 23, 2026 2:42 PM ET
Data refreshes hourly during market hours. Next update: 3:42 PM
Data refreshes hourly during market hours. Next update: 3:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGNX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 64 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 72 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 56 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 47 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$153 | 59 HOLD |
